Amarin Spotlights VASCEPA’s 33% Triglyceride Cut, $4,200 WAC and Guideline Backing
AMRN•Amarin emphasized that VASCEPA delivers a 33% median triglyceride reduction without raising LDL-C and carries a $4,200 annual WAC versus $40,000 for new APOC3 injectables, supporting broad payer coverage. The drug’s 30 million global prescriptions and ACC/AHA guideline reaffirmation bolster its first-line status in severe hypertriglyceridemia.
1. Injectable APOC3 Therapies Enter sHTG Treatment Landscape
Injectable APOC3 therapies have been approved for patients with severe hypertriglyceridemia (TG ≥500 mg/dL), offering a novel approach to reduce risk of acute pancreatitis in high-risk individuals.
2. VASCEPA’s Proven Lipid Reductions
VASCEPA achieved a 33% median triglyceride reduction versus placebo at 12 weeks, with roughly half of patients reaching levels below 500 mg/dL, and showed no associated LDL-C increases.
3. Cost Advantage and Coverage
VASCEPA’s annual WAC of $4,200 contrasts with the $40,000 WAC for injectable APOC3 therapies, supporting broad reimbursement by payers, PBMs and managed care through established utilization controls.
4. Guideline and Market Endorsement
With over 30 million global prescriptions, VASCEPA has been reaffirmed by the 2026 ACC/AHA guidelines and endorsed by 70+ medical societies as a first-line therapy for elevated triglycerides.
